Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
72.33% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
SYM · Jun 25, 2022
Symbotic Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001837240-22-000008General Corporate
Evidence method
Level · gp.fundamentals.gross_margin
17.97% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-18.82% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
20.02% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History20 statesSelf-history eligible
Jun 25, 20220/4 normalizedLevel 3Sep 24, 20220/7 normalizedLevel 3Dec 24, 20220/7 normalizedLevel 3Mar 25, 20230/7 normalizedLevel 3Jun 24, 20230/8 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 30, 20230/8 normalizedLevel 3Mar 30, 20240/8 normalizedLevel 3Jun 29, 20244/8 normalizedLevel 3Dec 30, 20230/8 normalizedAmended as filedMar 30, 20240/8 normalizedAmended as filedJun 29, 20244/8 normalizedAmended as filedSep 28, 20247/8 normalizedLevel 3Dec 28, 20247/8 normalizedLevel 3Mar 29, 20256/7 normalizedLevel 3Jun 28, 20257/7 normalizedLevel 3Sep 27, 20257/7 normalizedLevel 3Dec 27, 20257/7 normalizedLevel 3Mar 28, 20267/7 normalizedLevel 3Jun 27, 20267/7 normalizedLevel 4
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.